The latest price target for Revolution Medicines (NASDAQ:RVMD) was reported by Wedbush on December 6, 2024. The analyst firm set a price target for $67.00 expecting RVMD to rise to within 12 months (a possible 50.93% upside). 42 analyst firms have reported ratings in the last year.

The latest analyst rating for Revolution Medicines (NASDAQ:RVMD) was provided by Wedbush, and Revolution Medicines maintained their outperform rating.

The last upgrade for Revolution Medicines Inc happened on April 10, 2024 when Raymond James raised their price target to $48. Raymond James previously had an outperform for Revolution Medicines Inc.

There is no last downgrade for Revolution Medicines.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Revolution Medicines, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Revolution Medicines was filed on December 6, 2024 so you should expect the next rating to be made available sometime around December 6, 2025.

While ratings are subjective and will change, the latest Revolution Medicines (RVMD) rating was a maintained with a price target of $70.00 to $67.00. The current price Revolution Medicines (RVMD) is trading at is $44.39, which is out of the analyst’s predicted range.